Principle Wealth Partners’s Nektar Therapeutics NKTR Stock Holding History

Principle Wealth Partners’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,000	Closed	-$48	–	317
2022 Q3	$48	Hold	1,000	–	–	﹤0.01%	292
2022 Q2	$57K	Hold	1,000	–	–	0.01%	301
2022 Q1	$81K	Hold	1,000	–	–	0.01%	313
2021 Q4	$203K	Hold	1,000	–	–	0.02%	314
2021 Q3	$269K	Hold	1,000	–	–	0.03%	262
2021 Q2	$257K	Hold	1,000	–	–	0.03%	278
2021 Q1	$300K	Hold	1,000	–	–	0.04%	235
2020 Q4	$255K	Buy	+1,000	New	+$258K	0.03%	242

Other funds holding NKTR

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Principle Wealth Partners's NKTR Position: Q4 2022 in Review

Principle Wealth Partners sold out of Nektar Therapeutics (NKTR) in Q4 2022, closing a stake of 1,000 shares — an estimated $48 sold.

Principle Wealth Partners first reported a position in NKTR in Q4 2020 and held it in 8 quarters. The position peaked at $300K in Q1 2021. 214 funds tracked by Wall St. Rank hold NKTR as of Q4 2022.

Principle Wealth Partners reported no remaining Nektar Therapeutics position as of Q4 2022 after selling out during the quarter.
Principle Wealth Partners sold 1,000 Nektar Therapeutics shares in Q4 2022, an estimated $48.
Principle Wealth Partners first reported a position in Nektar Therapeutics in Q4 2020 and held it in 8 quarters.
Principle Wealth Partners's Nektar Therapeutics position peaked at $300K in Q1 2021.
214 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2022.

Based on Principle Wealth Partners's 13F filing for Q4 2022, filed 2 Feb 2023.